ON012380 inhibited the growth of cells expressing the wild-type Bcr–Abl protein and all of the imatinib-resistant kinase domain mutations, even T315I, at a concentration of less than 10 nM.
5, 6 Given the requirement for dimerization for kinase activation, it is conceivable that the deletion mutants have a dominant-negative effect on the native BCR-ABL by formation of heterodimers ...
Tyrosine kinase inhibitors (TKIs ... leading to an increase in BCR-ABL levels. Intolerance, on the other hand, means the ...
Sino-American biopharma Ascentage Pharma has announced that olverembatinib has been granted Breakthrough Therapy Designation ...
Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the ...
By Daniella Parra Ascentage Pharma (NASDAQ: AAPG; HKEX) said that its drug Olverembatinib is the first China-approved ...
Cite this: Abl Tyrosine Kinase Inhibitors for Overriding Bcr-Abl/T315I: From the Second to Third Generation - Medscape - Sep 01, 2008.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback